Lee Kang-Po, Huang Hui-Chi, Tsai Jui-Yao, Hsu Li-Chi
Department of Neurology, E-Da Hospital, Kaohsiung, Taiwan.
School of Medicine for International Students, College of Medicine, I-Shou University, Kaohsiung, Taiwan.
eNeurologicalSci. 2023 Jul 17;32:100474. doi: 10.1016/j.ensci.2023.100474. eCollection 2023 Sep.
Whether patients with stroke and cancer have specific characteristics remains controversial. In addition, research regarding the effects of individual cancer types on stroke outcomes remains scarce. This study investigated the mortality and stroke recurrence rates in patients with stroke and concomitant cancer and evaluated outcome predictors.
This study retrospectively enrolled 2610 patients in the Taipei Veterans General Hospital Stroke Registry registered from January 2019 to December 2020. A total of 1868 patients were included after excluding those without acute ischemic stroke or hospitalization. The patients were then categorized into the following diagnostic groups: cancer-associated stroke (CAS), stroke and inactive cancer, and stroke without cancer. The discharge mortality rate, 1-year mortality rate, and 1-year stroke recurrence rate were compared. Multiple clinical characteristics and comorbidities-age, sex, stroke severity, coagulopathy, common vascular risk factors, and acute stroke treatment-were also assessed.
A total of 302 (16.2%) patients had concomitant cancer; 39 (2.1%) patients were classified as having CAS and 263 (14.1%) as having stroke with inactive cancer. The baseline characteristics, stroke severity, and type of acute reperfusion therapy were similar among the three groups. However, the stroke recurrence and mortality rates were much higher in the patients with CAS in both short-term and long-term follow-up. The 30-day and 1-year mortality rates for the CAS, inactive cancer, and no cancer groups were 17.9%, 12.5%, and 4.7%, ( < 0.001) and 51.3%, 33.8%, and 12.4%, ( 0.001) respectively.
Patients with stroke and active cancer had similar stroke severity. However, the 1-year mortality and stroke recurrence rates were higher in these patients than in patients with inactive cancer or the control group.
中风和癌症患者是否具有特定特征仍存在争议。此外,关于个体癌症类型对中风结局影响的研究仍然匮乏。本研究调查了中风合并癌症患者的死亡率和中风复发率,并评估了结局预测因素。
本研究回顾性纳入了2019年1月至2020年12月在台北荣民总医院中风登记处登记的2610例患者。排除无急性缺血性中风或未住院的患者后,共纳入1868例患者。然后将患者分为以下诊断组:癌症相关性中风(CAS)、中风合并非活动性癌症和无癌症的中风。比较出院死亡率、1年死亡率和1年中风复发率。还评估了多种临床特征和合并症——年龄、性别、中风严重程度、凝血障碍、常见血管危险因素和急性中风治疗情况。
共有302例(16.2%)患者合并癌症;39例(2.1%)患者被归类为患有CAS,263例(14.1%)为患有非活动性癌症的中风。三组患者的基线特征、中风严重程度和急性再灌注治疗类型相似。然而,在短期和长期随访中,CAS患者的中风复发率和死亡率均高得多。CAS组、非活动性癌症组和无癌症组的30天和1年死亡率分别为17.9%、12.5%和4.7%(<0.001)以及51.3%、33.8%和12.4%(<0.001)。
中风合并活动性癌症患者的中风严重程度相似。然而,这些患者的1年死亡率和中风复发率高于非活动性癌症患者或对照组。